Hypertension: ReCor Launches Post-Market Study of Next-Gen Paradise System

Fri, 02/15/2013 - 12:26pm
Mass Device

ReCor Medical enrolls the 1st patients in a post-market study of its ultrasound-based renal denervation therapy in treatment of resistant high blood pressure.

ReCor's Paradise renal denervation system

California medical device startup ReCor Medical launched a post-market study of its next-generation Paradise renal denervation system in treatment of patients with resistant high blood pressure.

The 50-patient study has already enrolled patients at a participating facility in the Netherlands with the Paradise device, the only renal denervation device on the European market that treats high blood pressure with ultrasound rather than radiofrequency.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.